Long-term oncologic outcomes of neoadjuvant concurrent chemoradiotherapy with capecitabine and radical surgery in locally advanced rectal cancer = 10-year experiences at a single institution

다국어 초록 (Multilingual Abstract)

Purpose: Oral capecitabine has demonstrated to be safe and efficient as neoadjuvant concurrent chemoradiotherapy (NCRT) for locally advanced rectal cancers. The aim of this study was to evaluate the long-term oncologic outcomes of NCRT with capecitabine and radical surgery.
Methods: From January 2000 to June 2010, 238 patients were treated at our center for locally advanced rectal cancers using conventional NCRT with capecitabine and radical surgery. Univariate and multivariate analyses were used to evaluate the factors associated with oncologic outcomes with log rank and Cox regression tests.
Results: The incidence of grade >3 capecitabine-related toxicity was found to be 4.6%. A pathologic complete response was observed in 14.7% of patients. The 5-year overall and 5-year disease-free survival rate, local and systemic recurrence rate were 82.8%, 75.1%, 4.8%, and 20.3%. Abdominoperineal resection and node-positive disease were independent prognostic factors of 5-year overall survival, 5-year disease-free survival, and systemic recurrence.
Conclusion: NCRT with capecitabine and radical surgery showed favorable long-term oncologic outcomes with benefits of acceptable toxicity and convenience. We suggest that capecitabine can be one of the favorable therapeutic options for NCRT in rectal cancer.

목차 (Table of Contents)

• INTRODUCTION
• METHODS
• RESULTS
• DISCUSSION
• REFERENCES

참고문헌 (Reference)

1 Sawada N., "X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine(Xeloda)in human cancer xenografts" 5 : 2948-2953, 1999

2 Ishikawa T., "Tumor selec tive delivery of 5-fluorouracil by cape citabine, a new oral fluoropyrimidine car bamate, in human cancer xenografts" 55 : 1091-1097, 1998

3 Fernandez-Martos C., "The role of capecitabine in locally ad vanced rectal cancer treatment : an update" 72 : 1057-1073, 2012

4 Clavien PA., "The Clavien-Dindo classification of surgical complications : five-year ex pe rience" 250 : 187-196, 2009

5 Sauer R., "Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer : re sults of the German CAO/ARO/AIO-94 ran domized phase III trial after a median followup of 11 years" 30 : 192633-, 2012

6 Gerard JP., "Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers : results of FFCD 9203" 24 : 4620-4625, 2006

7 Kim JS., "Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer" 54 : 403-408, 2002

8 Chan AK., "Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer-is it equivalent to 5-FU infusion plus leucovorin and radiotherapy?" 76 : 1413-1419, 2010

9 Sauer R., "Pre operative versus postoperative chemo radiotherapy for rectal cancer" 351 : 1731-1740, 2004

10 Roh MS., "Pre operative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum : NSABP R-03" 27 : 5124-5130, 2009

11 Dellas K., "Phase II trial of pre operative radiochemotherapy with con cu rrent bevacizumab, capecitabine and oxaliplatin in patients with locally ad vanced rectal cancer" 8 : 90-, 2013

12 Landry JC., "Phase II Trial of Preoperative Radiation With Concu rrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin(FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer : 5-Year Clinical Outcomes ECOGACRIN Cancer Research Group E3204" 20 : 615-616, 2015

13 Hartley A., "Path ological complete response following pre-operative chemoradiotherapy in rectal cancer : analysis of phase II/III trials" 78 : 934-938, 2005

14 Van Cutsem E., "Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer : results of a large phase III study" 19 : 4097-4106, 2001

15 Scheithauer W., "Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial" 14 : 1735-1743, 2003

16 Kim NK., "Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer : impact of postirra diated pathologic downstaging on local recurrence and survival" 244 : 1024-1030, 2006

17 Lange MM., "Long-term results of rectal cancer surgery with a systematical operative approach" 20 : 1806-1815, 2013

18 Guillem JG., "Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer" 241 : 829-836, 2005

19 Abushullaih S., "Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine : a single-institution experience" 20 : 310-, 2002

20 Rich TA., "Four decades of continuing innovation with fluorouracil : current and future approaches to fluorouracil chemoradiation therapy" 22 : 2214-2232, 2004

21 Cassidy J., "First-line oral capecitabine therapy in metastatic colo rectal cancer : a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin" 13 : 566-575, 2002

22 Wong SJ., "Efficacy endpoints of radiation therapy group protocol 0247 : a randomized, phase 2 study of neoadjuvant radiation therapy plus con current capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer" 91 : 116-123, 2015

23 National Institutes of Health, "Common ter mi nology criteria for adverse events (CTCAE) version 4.0" National Institutes of Health, National Cancer Institute, U.S. Department of Health and Human Services 2009

24 Bosset JF., "Chemotherapy with preoperative radio therapy in rectal cancer" 355 : 111423-, 2006

25 Hofheinz RD., "Chemoradio therapy with capecitabine versus fluorouracil for locally advanced rectal cancer : a randomised, multicentre, noninferiority, phase 3 trial" 13 : 579-588, 2012

26 Kovach JS, "Cellular phar macology of fluorinated pyrimidines in vivo in man" 7 : 13-25, 1989

27 Twelves CJ., "Capecitabine/oxaliplatin, a safe and active firstline regimen for older patients with metastatic colorectal cancer : post hoc analysis of a large phase II study" 5 : 101-107, 2005

28 Twelves C., "Capecitabine as adjuvant treatment for stage III colon cancer" 352 : 2696-2704, 2005

29 Law WL., "Abdominoperineal resection is associated with poor oncological outcome" 91 : 1493-1499, 2004

30 Wang L., "Abdo minoperineal excision following preoperative radiotherapy for rectal cancer : unfavorable prognosis even with negative circumferential resection margin" 20 : 9138-9145, 2014